CaliberCos Inc. (CWD): Nasdaq/NYSE listing notice — CaliberCos receives Nasdaq bid price deficiency notice; 180-day cure period through Nov 11, 2024

CaliberCos Inc.

Stock closed below $1.00 for 30 consecutive business days; non-compliant with Nasdaq Listing Rule 5550(a)(2).
180-day grace period ends November 11, 2024; compliance requires $1.00 closing bid for 10 consecutive days.
If not cured, company may qualify for additional 180-day period subject to meeting initial listing criteria and reverse split intent.
Failure to regain compliance may lead to delisting; company intends to monitor and consider all options.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.95

CaliberCos Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5550(a)(2)

Exact text from the filing

May 14, 2024, CaliberCos Inc. (the “Company” or “Caliber”) received a letter from the Listing Qualifications Staff (the “Staff”) of the Nasdaq Stock Market LLC (“Nasdaq”) indicating that the bid price of the Company’s Class A common stock, par value $0.001 per share (the “Common Stock”), had closed below $1.00 per share for 30 consecutive business days and, as a result, the Company is not in compliance with Nasdaq Listing Rule 5550(a)(2), which sets forth the minimum bid price requirement for continued listing on the Nasdaq Capital Market (the “Minimum Bid Requirement”). Nasdaq’s notice has no

View on SEC.gov

20 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

CaliberCos Inc. filing history →

Source: SEC EDGAR

accession 0001627282-24-000074

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.